重组人脑利钠肽联合瑞舒伐他汀钙治疗心力衰竭的疗效

Therapeutic effect of recombinant human brain natriuretic peptide combined with rosuvastatin calcium for heart failure

目的 观察重组人脑利钠肽联合瑞舒伐他汀钙治疗心力衰竭的疗效。方法 选取2021年1月—2023年6月天津市东丽区中医医院收治的心力衰竭患者56例,根据抽签法分为A组与B组,各28例。A组予以瑞舒伐他汀钙连续治疗12周,B组在A组基础上予以重组人脑利钠肽连续治疗7 d。比较2组临床疗效,治疗前后心功能指标[心排血指数(CI)、每搏输出量(SV)以及左心室射血分数(LVEF)]、心肌损伤标志物[血清肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)]、血脂指标(血清三酰甘油、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇),不良反应。结果 B组总有效率高于A组(96.43%vs. 71.43%,χ^(2)=4.766,P=0.029)。治疗12周后,2组CI、SV、LVEF升高,且B组高于A组(P<0.01);2组血清CK-MB、cTnI水平降低,且B组低于A组(P<0.01);2组血清三酰甘油、低密度脂蛋白胆固醇水平降低,血清高密度脂蛋白胆固醇水平升高,且B组降低/升高幅度大于A组(P<0.01)。B组与A组不良反应总发生率比较,差异无统计学意义(7.14%vs. 10.71%,P=1.000)。结论 心力衰竭患者接受重组人脑利钠肽联合瑞舒伐他汀钙治疗,可明显提高临床疗效和心功能,减轻心肌损伤,有效调节血脂,且不会增加不良反应发生风险。

Objective To observe therapeutic effect of recombinant human brain natriuretic peptide combined with rosuvastatin calcium for heart failure.Methods Fifty-six patients with heart failure admitted to Tianjin Dongli District Traditional Chinese Medicine Hospital from January 2021 to June 2023 were selected and divided into the group A and the group B of 28 cases each according to the lottery method.The group A was treated with rosuvastatin calcium for 12 weeks,and the group B was treated with recombinant human brain natriuretic peptide for 7 days on the basis of the group A.Clinical efficacy,cardiac function indexes(CI,SV and LVEF),myocardial injury markers(CK-MB,cTnI),lipid indexes(serum TG,LDL-C and HDL-C)before and after treatment,and adverse reactions were compared between the two groups.Results The total effective rate of the group B was higher than that of the group A(96.43%vs.71.43%,χ2=4.766,P=0.029).After treatment of 12 weeks,CI,SV and LVEF increased in the two groups,and the group B were higher than those of the group A(P<0.01);Serum CK-MB and cTnI levels decreased in the two groups,and the group B were lower than those of the group A(P<0.01);Serum TG and LDL-C levels decreased and serum HDL-C level increased in the two groups,and the decrease/increase in the group B were greater than those in the group A(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the group B and the group A(7.14%vs.10.71%,P=1.000).Conclusion Patients with heart failure treated with recombinant human brain natriuretic peptide and rosuvastatin calcium can get significantly clinical effect and cardiac function,which can reduce myocardial injury and effective lipid regulation,and without increasing the incidence of adverse reactions.